Drug Profile


Alternative Names: ABT-RTA-408; RTA-408

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer AbbVie; Friedreichs Ataxia Research Alliance; Reata Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Small molecules; Triterpenes
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Friedreich's ataxia; Mitochondrial disorders; Ocular inflammation; Ocular pain
  • Phase I/II Malignant melanoma
  • Phase I Non-small cell lung cancer
  • Discontinued Duchenne muscular dystrophy; Radiation-induced skin damage

Most Recent Events

  • 13 Sep 2017 Omaveloxolone receives Orphan Drug status for Malignant melanoma in USA
  • 22 Jun 2017 Omaveloxolone receives Orphan Drug status for Friedreich's ataxia in USA
  • 01 Jun 2017 Efficacy and adverse events data from a phase II trial in Friedreich's ataxia released by Reata Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top